The experimental therapy tozorakimab from AstraZeneca was superior to a placebo at reducing the rate of moderate to severe exacerbations, or sudden episodes of symptom worsening, in adults with ...
Clinical Trials Arena on MSN
AstraZeneca reports positive data from phase III trial of efzimfotase alfa
The programme enrolled 196 children, adolescents, and adults with either paediatric-onset or adult-onset HPP.
GD analyst, Vinie Varkey notes that tozorakimab could capture a "significant patient share" as an add-on therapy in COPD.
March 27 () - AstraZeneca said on Friday its experimental respiratory treatment tozorakimab showed a meaningful reduction in ...
A phase 3 trial of AstraZeneca’s rare metabolic disease prospect has missed its primary endpoint, raising doubts about the ...
Tozorakimab met the primary goal in two late-stage clinical trials, reducing the rate at which patients’ symptoms worsened, ...
A key question for ESO-T01 and other in vivo candidates will be the durability of their cancer eradication. While the ...
AstraZeneca PLC (NASDAQ:AZN) has delivered a solid trailing 12 months, with shares up 31.43% over the past year. Year-to-date ...
AstraZeneca PLC (NYSE:AZN) is one of the 12 Best UK Stocks to Buy According to Hedge Funds. On March 16, 2026, AstraZeneca ...
French biotech Abivax has been the subject of intense takeover speculation for months. But a spokesperson denied a report by La Lettre that AstraZeneca was ...
The company is establishing commercial production capabilities to fuel plans to launch autologous CAR T cell therapies in ...
By Pushkala Aripaka, Nithyashree R B and Maggie Fick March 27 (Reuters) - AstraZeneca's experimental drug tozorakimab reduced ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results